In ER/PR-positive and HER2-negative breast cancer patients, the overall and disease-free survival rates did not evidence significant differences between high and low IGF-1/IGF-1R expression groups (Figure 1A,B). This evidence concerns the gene ERBB2 and breast carcinoma.